A pilot study to evaluate the effect of CT1812 treatment on synaptic density and other biomarkers in Alzheimer’s disease

A pilot study to evaluate the effect of CT1812 treatment on synaptic density and other biomarkers in Alzheimer’s disease

Abstract Background Effective, disease-modifying therapeutics for the treatment of Alzheimer’s disease (AD) remain a large unmet need. Extensive evidence suggests that amyloid beta (Aβ) is central to AD pathophysiology, and Aβ oligomers are among the most toxic forms of Aβ. CT1812 is a novel brain p...

Full description

Bibliographic Details
Main Authors: Christopher H. van Dyck, Adam P. Mecca, Ryan S. O’Dell, Hugh H. Bartlett, Nina G. Diepenbrock, Yiyun Huang, Mary E. Hamby, Michael Grundman, Susan M. Catalano, Anthony O. Caggiano, Richard E. Carson
Format: Article
Language:English
Published: BMC 2024-01-01
Series:Alzheimer’s Research & Therapy
Subjects:
Alzheimer’s disease
Sigma-2 receptor
Amyloid beta oligomers
SV2A PET
FDG PET
Biomarkers
Online Access:https://doi.org/10.1186/s13195-024-01382-2

Internet

https://doi.org/10.1186/s13195-024-01382-2

Similar Items